Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
QVA149, QAB149, NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,042 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
73
States / cities
Birmingham, Alabama • Montgomery, Alabama • Mesa, Arizona + 60 more
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QVA149 in COPD Patients

NCT02487446
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
58
States / cities
Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Indacaterol/Glycopyrrolate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol/glycopyrrolate, indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
QVA149, QAB149, NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Huntsville, Alabama • *See Various Dept.'s*, Arizona • Tempe, Arizona + 46 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, NVA237, tiotropium, Salbutamol/albuterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
NVA237, Long-acting beta 2-agonist (LABA), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
61
States / cities
Gulf Shores, Alabama • Mobile, Alabama • Tucson, Arizona + 52 more
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more